Glycovir

• CAS: 131262-82-3
• Catalog Number: ACM131262823-1
• Category: Inhibitors
• Molecular Weight: 499.64
• Molecular Formula: C26H45NO8
• Description: Glycovir, also known as SC-49483, is an anti-HIV prodrug. Glycovir is an alpha-glucosidase-1 inhibitor, and a candidate anti-HIV agent targeted against viral glycoprotein processing in host cell endoplasmic reticulum.
• Synonyms: Glycovir; SC 49483; SC-49483; SC49483; p-N-butyl-DNJ; Perbutylated-N-butyl-1-deoxynojiromycin
• IUPAC Name: (2R,3R,4R,5S)-1-butyl-2-((butyryloxy)methyl)piperidine-3,4,5-triyl tributyrate
• Canonical SMILES: CCCC(OC[C@H]1N(CCCC)C[C@H](OC(CCC)=O)[C@@H](OC(CCC)=O)[C@@H]1OC(CCC)=O)=O
• InChI: InChI=1S/C26H45NO8/c1-6-11-16-27-17-20(33-22(29)13-8-3)26(35-24(31)15-10-5)25(34-23(30)14-9-4)19(27)18-32-21(28)12-7-2/h19-20,25-26H,6-18H2,1-5H3/t19-,20+,25-,26-/m1/s1
• InChI Key: MKGDNVHZSCXBKR-KYVQNOJUSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >3 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 131262-82-3 (free base); 238075-09-7 (free base)
• Biological Target: Glycovir is an alpha-glucosidase-1 inhibitor, and a candidate anti-HIV agent targeted against viral glycoprotein processing in host cell endoplasmic reticulum.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 62.50; H, 9.08; N, 2.80; O, 25.62
• Exact Mass: 499.3145
• HS Tariff Code: 2934.99.03.00
• In Vitro Activity: TBD
• In Vivo Activity: The potential toxicity of perbutylated-N-butyl-1-deoxynojiromycin (p-N-butyl-DNJ, SC-49483), was evaluated in Sprague-Dawley rats after 4, 13, or 26 wk of oral administration at doses ranging from 300 to 3,670 mg/kg/day. In these studies, the target organs of p-N-butyl-DNJ effects were thyroid gland, salivary gland, stomach, and pancreas. The most prominent histologic change in these organs was the presence of clear or lightly eosinophilic vacuoles in the cytoplasm of thyroid follicular cells, gastric chief cells, salivary gland acinar cells, and exocrine pancreatic acinar cells. Ultrastructurally, these vacuoles were consistent with dilated rough endoplasmic reticulum, which sometimes contained homogeneously stained, moderately electron-dense material. The vacuoles in thyroid follicular cells contained pale eosinophilic colloidlike material consistent with accumulated thyroglobulin, as shown by immunohistochemical staining methods. The biological functions of these organs were not adversely affected as evidenced by the absence of clinical signs and the results of selected hormonal analyses. The morphologic changes were completely reversed after a 4-wk recovery period. It is believed that morphologic changes in thyroid follicular cells, salivary gland acinar cells, pancreatic acinar cells, and gastric chief cells were the result of nonspecific inhibition of host alpha-glucosidase(s) by p-N-butyl-DNJ, causing clinically silent perturbation in host cell glycoprotein processing and/or glycoprotein transport.; Reference: Toxicol Pathol. Sep-Oct 1996;24(5):531-8. https://pubmed.ncbi.nlm.nih.gov/8923673/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).